Evaluation of REMIFENTANIL as an alternative to curare for rapid sequence anesthetic induction in patients at risk of gastric fluid inhalation - REMICrush

CHU Nantes0 个研究点目标入组 1,150 人开始时间: 2019年5月14日最近更新: 2021年5月3日

适应症

试验速览

暂无简介。

•- Female or male.
•- Aged 18 to 80 years old
•- Intervention requiring general anesthesia with orotracheal intubation
•- Anesthetic management with indication of induction in rapid sequence
•- Risk of gastric fluid inhalation defined by at least one of the following criteria: fasting period < 6:00 am, digestive obstruction, functional ileus, vomiting < 12:00 pm orthopedic trauma < 12:00 pm, history of severe GERD and/or hiatal hernia and/or gastroparesis and/or dysautonomy and/or gastroesophageal surgery
•- Existence of informed and signed consent from the patient, or in the absence of an emergency procedure
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 850
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 300

•- impossible Intubation planned
•- Known or suspected history of allergy to curares and/or remifentanil
•- History of neuromuscular disease contraindicating the use of curares
•- History of residual curarization
•- History of malignant hyperthermia
•- Preoperative respiratory distress (SpO2 < 95% in ambient air)
•- Preoperative shock (under vasopressor amines)
•- Patient in cardiorespiratory arrest
•- A woman of childbearing potential and of childbearing potential who has an ongoing pregnancy and/or clinical signs suggestive of an ongoing pregnancy and/or who does not have a contraceptive or contragestive method and has had unprotected sexual relations within 15 days after the last menstrual period.
•- Patients under guardianship or curatorship
•- Intended use of ETOMIDATE for rapid sequence induction

发起方